

## Special Issue

# Research and Treatment of Hepatocellular Carcinoma

### Message from the Guest Editor

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, driven by factors such as chronic liver disease, viral hepatitis, and metabolic disorders. This Special Issue highlights recent advances in HCC research, including molecular pathogenesis, diagnostic biomarkers, and innovative therapeutic strategies such as immunotherapy, targeted therapy, and combination treatments. It also explores challenges in early detection, treatment resistance, and personalized medicine. By integrating cutting-edge research and clinical insights, this collection aims to foster interdisciplinary collaboration and improve outcomes for HCC patients. Contributions from experts provide a comprehensive overview of current progress and future directions in HCC management.

### Guest Editor

Dr. Chung Cheung Thomas Yau

Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China

### Deadline for manuscript submissions

30 June 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/244704](https://mdpi.com/si/244704)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)